Single Cell Discoveries B.V.. (9/14/26). "Press Release: Single Cell Discoveries Acquires TATAA Biocenter to Create an End-to-End Precision Biology CRO". Utrecht & Gothenburg.

	Organisation	Single Cell Discoveries B.V.
	Today	Single Cell Discoveries (Group)
	Group	Single Cell Discoveries (Group)
	Organisation 2	TATAA Biocenter AB
	Group	Single Cell Discoveries (Group)
	Product	drug development services
	Product 2	private equity
	Index term	TATAA Biocenter–Single Cell Discoveries: investment, 202609 acquisition €na of TATAA Biocenter by Single Cell Discoveries backed by Care Equity
	Person	Muraro, Mauro (Single Cell Discoveries 202609 CEO + Co-Founder)

Single Cell Discoveries (SCD), a specialist contract research organization (CRO) focused on discovery transcriptomics, has completed the acquisition of TATAA Biocenter, a globally recognized leader in qPCR, bioanalytical services, and molecular assay development. The combination creates one of Europe’s few specialist CROs able to take a molecular target from discovery to a validated, regulatory-ready result. Financial terms were not disclosed.

Together, the two organizations employ approximately 50 scientists across Utrecht and Gothenburg, supporting pharmaceutical, biotechnology, and academic customers from discovery through validation and clinical development.

SCD contributes single-cell sequencing, spatial transcriptomics, high-throughput RNA sequencing, bioinformatics, and multi-omics. TATAA adds qPCR, dPCR, proteomics, RNA and DNA sequencing, and GLP/GCLP-compliant bioanalysis. A target identified by single-cell sequencing can now be confirmed with spatial transcriptomics or proteomics, then developed into a qPCR or RNA-seq assay validated under GCLP or GLP in Gothenburg, without the samples or the data leaving the group. SCD now pairs research-grade innovation with validated workflows suitable for preclinical and clinical use.

“This is a natural fit,” said Mauro Muraro, CEO of Single Cell Discoveries. “Customers kept telling us the same thing: they loved working with us on discovery but had to go elsewhere to validate targets for a clinical program. TATAA closes that gap. As drug developers consolidate their outsourcing, working with fewer partners across more of the development pathway, this is the right move: the discovery-to-validation handover is one of the points where fragmentation costs sponsors the most time.”

“Scientifically, this offers discovery coupled with rigor,” said Sofia Adolfsson, Scientific Officer of TATAA Biocenter. “SCD’s single-cell and spatial technologies generate exceptional insight, and our GLP/GCLP-compliant qPCR and assay development can now validate those findings — without customers switching providers, protocols, or data formats partway through a program.”

For existing customers, projects, teams, workflows, and quality systems continue unchanged, and current contacts remain the point of entry. TATAA will continue to operate from Gothenburg with the same scientists. What is new is the option to extend a program across both organizations: combined services are available from September 2026.

“Pairing regulated molecular analysis with SCD enables us to better serve clients as they advance towards the clinic, translating the powerful discoveries from single cell and spatial omics into validated biomarker assays,” says Peter Batesko, Lead Director of SCD and Managing Partner of Care Equity, an investment firm specialized in outsourced drug development services which provided growth capital to SCD in 2022. “We are excited to see the teams combine their strengths and continue to build lasting, impactful client partnerships.”

Judith Vivie, COO and Mauro Muraro, CEO will lead the combined organization. The Gothenburg site will continue to be managed locally, with its scientific and customer-facing teams in place. Together, the two teams will continue to serve academic, biotech and pharma customers across the life sciences.

About SCD

SCD is a specialist precision biology CRO supporting pharmaceutical, biotechnology, and academic organizations from discovery through validation and clinical development. It combines single-cell sequencing, spatial transcriptomics, multi-omics, data science, molecular assay development, qPCR, dPCR, proteomics, and regulatory-ready bioanalysis in one organization. Customers work directly with the scientists who design, execute, and interpret their studies.

About TATAA Biocenter

TATAA Biocenter is a leading bioanalytical CRO specializing in high-precision molecular analyses that drive drug development. With over 20 years of experience, TATAA provides cutting-edge qPCR, dPCR, NGS, and proteomics-based solutions to support cell and gene therapy bioanalysis, biomarker discovery, and regulated assay development. Based in Gothenburg, Sweden, the company operates an ISO17025 -, GLP- and GCLP-accredited laboratory serving pharmaceutical, biotechnology, and academic organizations worldwide. TATAA Biocenter is part of Single Cell Discoveries.

Contact

K Pereni Sri Rajitha
Mauro Muraro
press@scdiscoveries.com
+31851146060

www.scdiscoveries.com
www.tataa.com

Record changed: 2026-09-25

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com